Table 3 QiSa medication indicator performance raw risk differences by sex

Indicator 6

Patients with heart failure and prescribed beta blocker

75.2% (n = 13,890/18,462)

77.5% (n = 13,920/17,964)

76.3% (n = 27,810/36,426)

RD = 2.3;

CI: 1.4; 3.1

Indicator 7

Patients after acute myocardial infarction and prescribed beta blocker

85.1%

(n = 702/825)

86.3% (n = 1,063/1,232)

85.8% (n = 1,765/2,057)

RD = 1.2;

CI: -1.9; 4.3

Indicator 8

eligible Patients with prescribed statins

35.2% (n = 15,383/43,666)

50.1% (n = 19,321/38,531)

42.2% (n = 34,704/82,197)

RD = 14.9;

CI: 14.2;15.6

Indicator 9

eligible Patients with heart failure and/or high blood pressure and prescribed ACE-inhibitors or AT-II antagonists

77.2% (n = 44,653/57,823)

80.6% (n = 42,668/52,921)

78.8% (n = 87,321/110,744)

RD = 3.4;

CI: 2.9; 3.9